Document:

alturaserviceagmt

                               SERVICES AGREEMENT

        This Agreement (the "Agreement"), dated April 15, 2002 (the "Effective
Date"), is by and between DNA Print DNA Print Genomics, a Utah corporation
having a principal place of business at 900 Cocoanut Ave, Sarasota, Florida
34236 (hereinafter "DNA Print"), and Altura, LLC, a California Limited Liability
Altura having a principal place of business at 20 Bronco St., Trabuco Canyon, CA
92679 (hereinafter "Altura").

        WHEREAS, DNA Print is engaged in developing complex genetic analytics and
information resource products; and

        WHEREAS, Altura is engaged in the business of providing various clinical
research and clinical program support services to research sponsors, research
centers and managed care organizations; and

        WHEREAS, DNA Print proposes to retain Altura to perform services on the
terms and conditions set forth in this Agreement;

        NOW THEREFORE, in consideration of the premises and the mutual promises and
undertakings herein contained, the parties agree as follows:

                1. Services

1.1     DNA Print shall retain Altura in order to develop a project plan and
        collect buccal DNA samples, patient bio-information and selected
        clinical data on the required number of patients to meet statistical
        significance up to a maximum 500 patients. The deliverables and scope
        of this project are described in Exhibit 1 and Exhibit 2 ("the
        Services").

                2. Compensation And Expenses

2.1     DNA Print shall pay Altura $xxx for the Services in accordance with
        this Agreement. The payment schedule is as follows:

o        $xxx (29%) is due upon signing of this agreement on April 15, 2002.
o        $xxx (29%) is due upon the patient enrollment start date.
o        $xxx (25%) is due upon the enrollment of 200 patients or statistically required patients.
o        $xxx (17%) is due upon the enrollment of 400 patients or statistically required patients.

o       Prior approval from DNA Print and Altura is required for all work outside
        the scope of this agreement. Altura billing rate is $2,500 per day
        ($312/hour). Out-of-scope examples include:

        - Creation of detailed policies and procedures for DNA Print
        - Creation of a statistical plan for project or statistical analysis of database
        - Creation of database to store clinical data or entry of data into database
        - More than one (1) meeting one at DNA Print's office in Florida.
        - Project management and execution services not listed but required for project

                                       1

2.2     All expenses and costs associated with the performance of this contract
        will be reimbursed by DNA Print. These expenses and costs include:

        - Shipping fees to and from medical group (s) or Altura (pass through cost
          to DNA Print)
        - Lab and document storage fees (pass through cost to DNA Print)
        - All appropriate out-of-pocket costs incurred by Altura such as travel
          expenses, print/copy, overnight mail, etc.).

2.3     Invoices shall be paid by DNA Print upon receipt of invoice from Altura.

                3. Confidentiality

3.1     DNA Print and Altura may disclose to each other certain proprietary,
        confidential, and/or trade secret information ("Confidential Information")
        in connection with the Services. The party disclosing Confidential
        Information shall be referred to as the "Discloser" and the party receiving
        Confidential Information shall be referred to as the "Recipient."

3.2     Recipient shall hold in strict confidence, from the Effective Date until
        ten (10) years after termination or expiration of this Agreement, whichever
        occurs first, all of Discloser's Confidential Information that is either
        (a) marked "Confidential" at the time of disclosure, or (b) designated by
        Discloser to be confidential in writing received by Recipient within thirty
        (30) days following disclosure.

3.3     Recipient shall not (a) use or disclose Discloser's Confidential
        Information except as expressly permitted by this Agreement, or (b)
        disclose Discloser's Confidential Information to any third party other than
        to those of the Recipient's employees and agents who (i) have a need to
        have access to such Confidential Information in order to perform the
        Services and (ii) agree in writing to comply with the confidentiality
        provisions of this Section 3.

3.4     This Section 3 imposes no obligation of confidentiality on Recipient with
        regard to any portion of the Discloser's Confidential Information:

        (a) that is part of the public domain at the time of disclosure; or

        (b) that becomes part of the public domain after the Effective Date
            without any unauthorized act by or omission of Recipient; or

        (c) if Recipient can demonstrate by written records that it had
            independently developed knowledge of such Confidential Information
            prior to or after the date of disclosure without use, reference to, or
            reliance upon Confidential Information disclosed to it by Discloser or
            the performance of Recipient's obligations pursuant to this Agreement;
            or

        (d) that is disclosed to Recipient by a third party who has the legal
            right to make such disclosure; or

                                       2

        (e) if permission to use or disclose said Confidential Information or to
            make use thereof is first obtained by Recipient in a writing signed by
            an authorized representative of Discloser; or

        (f) if Recipient is required by law, regulation, rule, act, or order of
            any court or other government authority or agency to disclose such
            Confidential Information; provided, however, that Recipient shall (i)
            give Discloser sufficient advance written notice to permit Discloser
            to seek a protective order or other similar order with respect to such
            Confidential Information, and (ii) thereafter disclose only the
            minimum Confidential Information required to be disclosed in order to
            comply, whether or not a protective order or other similar order is
            obtained by Discloser.

3.5     Disclosure of Confidential Information under this Agreement shall not be
        construed to create in or grant to Recipient any license, right, title,
        interest, or ownership in or to any of Discloser's Confidential
        Information.

3.6     Recipient shall use the same degree of care to protect the Discloser's
        Confidential Information as Recipient uses to protect its own confidential
        information, but in no event shall Recipient exercise anything less than a
        reasonable degree of care in protecting Discloser's Confidential
        Information.

3.7     Upon Discloser's request or at the termination or expiration of the
        Agreement pursuant to Section 4, Recipient shall return to Discloser any or
        all written, printed, visual, or digital media, documents, tapes, and other
        materials or substances containing Discloser's Confidential Information,
        including all copies and excerpts thereof. The return of Discloser's
        Confidential Information shall not relieve Recipient of its obligations of
        confidentiality pursuant to this Section 3.

3.8     Nothing in this Agreement shall be construed as granting or providing
        either party with any right, title, or interest in or to any of the other
        party's Confidential Information or other intellectual or proprietary
        rights of the other party.

                4. Term And Termination

4.1     This Agreement shall remain in full force and effect from the Effective
        Date until the two (2) year anniversary of such date or the completion of
        the Services, unless terminated earlier in accordance with the terms of
        this Agreement.

4.2     DNA Print may terminate this agreement on ninety (90) days notice once the
        samples and information are collected on the required number of
        statistically relevant subjects up to a maximum of five hundred (500)
        subjects.

4.3     In the event that either party commits a breach or default of any material
        term of this Agreement and that party (the "Defaulting Party") fails to
        remedy that default or breach within thirty (30) days after receipt of
        written notice of that breach from the other party, the party giving notice
        may, at its option, terminate this Agreement by sending written notice of
        termination ("Termination Notice") to the Defaulting Party. The Agreement

                                       3

        shall terminate three (3) business days after the date of the Termination
        Notice, and the parties shall retain all claims, causes of action,
        defenses, and other rights that they may have at law or in equity.

4.4     If under state or federal privacy laws, such as HIPAA, or if a medical
        group's legal or medical leadership determines it is not feasible to
        continue with the collection of samples and clinical information, Altura
        shall have the right to terminate this Agreement on written notice to DNA
        Print.

4.5     In the case of early termination of the Agreement by DNA Print pursuant to
        Section 4.3 or by Altura pursuant to Section 4.4, Altura shall use its
        reasonable efforts to terminate any outstanding commitments and discontinue
        all work under the Agreement. If termination is pursuant to Section 4.3 or
        Section 4.4, Altura shall not be entitled to any further compensation other
        than for: (i) unpaid fees for Services rendered and expenses incurred by
        Altura as authorized pursuant to this Agreement pending as of the date of
        termination (including any milestone or performance based compensation
        which arises from any milestones, goals or targets met after the date of
        termination but arising from work performed prior to the date of
        termination), and (ii) unpaid expenses for reasonable, non-cancelable
        obligations incurred or committed to be incurred by Altura pursuant to this
        Agreement pending as of the date of termination. If termination is by
        Altura pursuant to Section 4.3 or by DNA Print pursuant to Section 4.2,
        Altura shall be paid: (i) the total project cost referenced in Section 2.1,
        that remains outstanding at the date of termination, and (ii) unpaid
        expenses for reasonable, non-cancelable obligations incurred or committed
        to be incurred by Altura pursuant to this Agreement pending as of the date
        of termination.

4.5     In the event either party becomes insolvent, makes an assignment for the
        benefit of creditors, files a petition for bankruptcy, is the subject of a
        petition for bankruptcy which is not dismissed within (90) days from the
        filing thereof, becomes the subject of any receivership or admits in
        writing its inability to pay its debt generally as they become due, the
        other party may immediately terminate this Agreement by written notice of
        termination to the insolvent party and shall be entitled to recover any
        payments which could be recovered from the insolvent party in the event of
        default.

                5. Indemnification

5.1     DNA Print shall defend, indemnify, and hold harmless Altura and its
        subsidiaries, employees, insurers, officers, directors, affiliates, and
        agents, including medical groups and physicians contracted by Altura to
        perform the Services, from and against any claims, proceedings, or
        investigations (collectively "Claims") arising out of or in connection with
        DNA Print' use of information, materials, or data provided by Altura or
        medical groups and physicians to DNA Print pursuant to this Agreement,
        (including but not limited to Claims for misuse of information or violation
        of any right to privacy, patent infringement, product liability or injury
        resulting from the performance of the Services by or for DNA Print, and/or
        DNA Print' use of the results of the Services), including but not limited
        to amounts paid in settlement of Claims and costs and expenses, including
        reasonable attorneys' fees, incurred in connection with the defense or
        settlement of any such Claim. DNA Print' obligations under this Section 5.1
        shall not extend to Claims relating to or arising from Altura's negligence,
        wilful misconduct, or breach of this Agreement (including but not limited
        to Claims for misuse of information or violation of any right to privacy).

                                       4

5.2     Altura shall defend, indemnify, and hold harmless DNA Print and its
        subsidiaries, employees, insurers, officers, directors, affiliates, and
        agents from and against any Claims arising out of or in connection with the
        Altura's negligence, wilful misconduct, or breach of this Agreement
        (including but not limited to Claims for misuse of information or violation
        of any right to privacy), including but not limited to amounts paid in
        settlement of Claims and costs and expenses, including reasonable
        attorneys' fees, incurred in connection with the defense or settlement of
        such Claim.

5.3     The party seeking indemnity under this Section 5 (the "Indemnified Party")
        shall provide prompt written notice of the Claim to the other party (the
        "Indemnifying Party"). The Indemnifying Party shall have the sole right to
        choose counsel to defend any Claim, and shall have the sole right to settle
        or otherwise resolve any such Claim; provided, however, that settlement
        does not impose any obligation or liability on the Indemnified Party. The
        Indemnified Party, at its own expense, may be represented by separate
        counsel in addition to counsel selected by the Indemnifying Party.

                6. Publicity

6.1     Unless required by law, neither DNA Print nor Altura shall disclose the
        fact of, terms of, or subject matter of this Agreement to any third party
        without the prior written consent of the other executing party.

6.2     Both parties agree not to use any of other party's trademarks or trade
        names without the prior express written consent of the other party.

                7. Independent Contractor

7.1     Altura shall perform the Services under this Agreement only as an
        independent contractor, and nothing contained herein shall be construed to
        be inconsistent with that relationship or status. Altura, its employees,
        contractors, directors, and agents shall not be considered employees or
        agents of DNA Print. Neither party shall have any authority to bind the
        other party to any contract or obligation.

7.2     This Agreement shall not constitute, create, or in any way be interpreted
        as a joint venture, partnership, or business organization of any kind.

                8. Legal and Regulatory Compliance

8.1     Each party shall comply with all foreign and United States federal, state
        and local laws and regulations applicable to the Services and the use of
        the information arising from the Services, including but not limited to,
        all laws and regulations related to the confidentiality and security of
        personal and medical data (including the Health Insurance Portability and

                                       5

        Accessibility of 1996, as amended) and the use of information in the
        development of pharmaceutical products, diagnostic tests and medical
        devices (including the Food, Drug and Cosmetic Act, as amended), and any
        other laws and/or regulations relating to the maintenance, use,
        transmission or other activity concerning patient records and
        confidentiality of personal and medical data.

                9. Intellectual Property Rights

9.1     DNA Print acknowledges that during the course of providing the Services
        hereunder, Altura may use pre-existing or non-Services related procedural
        manuals, manged care research models and practices, proprietary
        information, personnel data and computer software of Altura. All
        information, software, techniques and methodologies transmitted by Altura
        to DNA Print or medical groups and physicians, or used by Altura during the
        course of performing the services are the proprietary and confidential
        information of Altura.

                10. Taxes

10.1    Any sales or use taxes determined to be applicable as a result of Services
        covered by this Agreement shall be the responsibility of Altura. Altura's
        Federal TAX I.D. is 33-0920460.

                11. Communications And Payments

11.1    Checks shall be made payable to: "Altura" and sent to:

                                    Altura, LLC
                                    20 Bronco St.
                                    Trabuco Canyon, CA 92679
                                    Attention:  Pete Fronte

11.2    Any notice required or permitted hereunder shall be in writing and shall be
        deemed given as of the date it is:

        (a) delivered by hand;

        (b) received or refused by Registered or Certified Mail, postage prepaid,
            return receipt requested; or

        (c) received by facsimile, as can be presumptively demonstrated by return
            fax or letter demonstrating successful facsimile transmission; and
            addressed to the party to receive such notice at the address (es)
            and/or facsimile telephone number(s) set forth below, or such other
            address as is subsequently specified to the notifying party by the
            receiving party in writing.

                                       6

If to Altura, notice should be sent to:

                                    Altura
                                    Attention:  Pete Fronte
                                    20 Bronco St.
                                    Trabuco Canyon, CA 92679
                                    Telephone Number:  949-858-3947
                                    Facsimile Number:  949-858-3161

If to DNA Print, notice should be sent to:

                                    DNA Print Pharmaceuticals Inc.
                                    900 Cocoanut Ave.
                                    Sarasota, Florida 34236
                                    Attention:  Tony Frudakis, Ph.D.

                12. Miscellaneous

12.1    Force Majeure

        Neither DNA Print nor Altura shall be liable for delays in performing or
        any failure to perform any of the terms of this Agreement caused by the
        effects of fire, strike, war, insurrection, government restriction or
        prohibition, or other causes reasonably beyond its control and without its
        fault, but the party failing to perform shall use all reasonable efforts to
        resume performance of this Agreement as soon as feasible. Any episode of
        force majeure which continues for sixty (60) days from the date of
        notification of its existence shall give the non-affected party the right
        to terminate this Agreement upon thirty (30) days additional notice.

12.2    Assignment

        Neither party shall have the right to assign this Agreement or any of the
        rights or obligations hereunder without the prior written consent of the
        other party, except that either party may assign this Agreement to a
        successor or assignee of substantially all of its business.

12.3    Entire Agreement; Modification

        This Agreement, and any exhibits incorporated herein by reference,
        constitute the entire agreement between the parties on the subject matter
        and supersede all prior contracts, agreements and understandings relating
        to the same subject matter between the parties. The parties intend this
        Agreement to be a complete statement of the terms of their agreement, and
        no change or modification of any of the provisions of this Agreement shall
        be effective unless it is in writing and signed by a duly authorized
        representative of Altura and DNA Print.

12.4    Governing Law

                                       7

        This Agreement shall be governed by, and construed in accordance with, the
        laws of the State of California and the United States, as though made and
        to be fully performed therein without regard to conflicts of laws
        principles thereof. All disputes relating in any way to this Agreement
        shall be resolved exclusively through arbitration conducted in accordance
        with the Commercial Arbitration Rule of the American Arbitration
        Association as then in effect. The arbitration hearing shall be held as
        soon as practicable. The arbitration hearing shall be held in Orange
        County, California and shall be before a single arbitrator selected by the
        parties in accordance with the Commercial Arbitration Rule of the American
        Arbitration Association pursuant to its rules on selection of arbitrators.
        The arbitrator shall render a formal, binding non-appealable resolution and
        award on each issue as expeditiously as possible but not more than ten (10)
        business days after the hearing. In any arbitration, the prevailing party
        shall be entitled to reimbursement of its reasonable attorneys fees and
        costs and the parties shall use all reasonable efforts to keep arbitration
        costs to a minimum.

12.5    Severability

        If any part of this Agreement shall be determined to be invalid or
        unenforceable by a court of competent jurisdiction or by any other legally
        constituted body having jurisdiction to make such determination, the
        remainder of this Agreement shall remain in full force and effect, provided
        that the part of the Agreement thus invalidated or declared unenforceable
        is not essential to the intended purposes of this Agreement.

12.6    Waiver

        The failure of either party to demand strict performance of any term or
        condition of this Agreement shall not constitute a waiver thereof or in any
        way limit or prevent subsequent strict enforcement of such term or
        condition.

12.7    Binding Effects

        The terms of this Agreement shall be binding upon and inure to the benefit
        of Altura, DNA Print and their respective successors and assigns.

12.8    Survival

        The obligations of Altura under Sections 3, 5, 9, and 10, and DNA Print'
        obligations under Sections 3, 5, and 10 shall survive termination of this
        Agreement.

IN WITNESS WHEREOF, the parties have indicated their acceptance of the terms of
this Agreement by the signatures set forth below on the dates indicated. Each
individual signing for a corporate entity hereby personally warrants his or her
legal authority to bind that entity.

ACCEPTED AND AGREED TO:

                                       8

DNA Print Pharmaceuticals Inc.              Altura

By:/s/Tony Frudakis                         By:/s/Pete Fronte

Name:  Tony Frudakis, Ph.D.                 Name:  Pete Fronte

Title:  CEO/CSO                             Title:  President

Date:  ___________________                  Date:  ____________________

                                       9

                            Exhibit 1 - Deliverables

      ALTURA DELIVERABLES (draft date 2/22/02 - need to confirm/complete)

1.      Project development services

        a) Review existing protocol and collection plan

                                       9

           - Confirm objectives and requirements
           - Provide feedback on viability of current plan and suggest options

        b) Develop project implementation plan
           - Describe key tasks and responsibilities for project
           - Suggest timelines and milestones
           - Gain feedback from DNA Print and adjust as needed
           - Complete implementation plan

        c) Identify and assess medical groups for participation
           - Make contact with administration and medical leadership of various medical groups
           - Assess ACE patient population, resources, structure and interest

        d) Sign contract with group
           - Select appropriate medical group (s)
           - Facilitate the signing of agreement (s) for project participation

2.      Program implementation services

        a) Conduct one planning/orientation meeting with selected medical group (s)
           - Prepare orientation and presentation material
           - Gain feedback & approval from DNA Print
           - Make arrangements for meeting including selecting and inviting participants
           - Conduct meeting to prepare participants and ensure success of project

        b) Facilitate the collection of the following per the study synopsis:
           - Up to 500 DNA samples (via swabs) of patients on the following Ace Inhibitors:
             Lisinipril, Quinapril, Enalapril, Benzapryl, Fosinopril and Ramapril
           - required bioinformation and clinical data on up to 500 patients that have
             provided DNA (specifics TBD)

        c) Weekly calls with group (s) in order to track project and problem solve
           - Maintain contact with project leader(s) and team
           - Track progress of project (enrollment, keys tasks, etc.)
           - Proactively identify problems and discuss with DNA Print
           - Ensure project course is consistent with project plan

        d) Bi-monthly site visits to actively assist with the implementation of program
           - In person meetings to gain update on project, trouble shoot and/or remove obstacles
           - Reeducate or reorient project teams as needed
           - Collect required documents for submission to DNA Print
           - Ensure quality of project and compliance to project design
3.      Project closure and follow-up services

        a) Ensure the completion and delivery of all samples and documents
           - Site closure visit to ensure delivery of all sample and documents
           - Reconcile tracking forms and packet deliveries with DNA Print

        b) Resolve any outstanding items and follow-up for DNA Print
           - Follow-up with site (s) in person or via phone as needed to ensure proper closure of
             project.
           - Conduct project summary meeting with DNA Print

                                       10

     DNA PRINT DELIVERABLES (draft date 2/22/02 - need to confirm/complete)

1. Provide input to development of reworded protocol, consent form, Bio-form and
   clinical form
2. Provide indemnification (if requested) to the investigators/ Provide sample
   collection materials to the sites
3. Provide DNA collection packets, bio-forms and clinical forms to sites
4. Provide labels with unique identifier numbers for samples, forms and physician's office
5. Provide ongoing advice on adequacy of patients with respect to entry into the study
6. Provide traceable delivery service (e.g., FedEx, UPS, Airborne) for shipment
   of samples and data back to DNA Print
7. Identify problems with data or sample collections and notify Altura
8. Perform all data entry deemed necessary for completion of the project
9. Provide long term storage of samples
10.Perform all necessary analyses necessary for the completion of the project

                  Exhibit 2 - Study Synopsis and Required Forms

1) Project Synopsis - draft is being discussed - insert once complete and agreed upon

2) Genetic Bioinformation Form - draft is being discussed - insert once complete and agreed upon

3) Clinical Information Form - draft is being discussed - insert once complete and agreed uponpennstatelicenseagmt

                                LICENSE AGREEMENT

        This License Agreement, effective upon the date of last signature herein
(the "Effective Date"), by and between The Penn State Research Foundation
(hereinafter referred to as "PSRF"), a non-profit corporation duly organized and
existing under the laws of the Commonwealth of Pennsylvania and having an office
at 304 Old Main, University Park, PA 16802, and DNAPrint Genomics Inc, a
corporation organized under the laws of the State of Florida (hereinafter
referred to as "LICENSEE"), having its principal office at 900 Cocoanut Avenue,
Sarasota, Florida 34236.

                                   WITNESSETH

        WHEREAS, Dr. Mark Shriver, employee of The Pennsylvania State University
(the "UNIVERSITY"), in the course of basic research, has collected certain human
DNA samples and certain subjectively measured and self-reported biogeographical
ancestry and ethnicity data, eye color, hair color & skin color pigmentation
data, and sun exposure history information relating to said samples ("SAMPLES &
TECHNICAL INFORMATION", as defined hereinbelow), filed as The Pennsylvania State
University Invention Disclosure No. XXXX-XXXX, and is described in Appendix B
attached herein below;

        WHEREAS, PSRF is dedicated to fostering and advancing scientific research
within the Commonwealth of Pennsylvania and, in particular, within the
UNIVERSITY and is responsible for developing discoveries and inventions made by
employees of the UNIVERSITY by evaluating invention disclosures, pursuing
patents, and pursuing licensing arrangements thereon;

        WHEREAS, PSRF is the owner of said SAMPLES & TECHNICAL INFORMATION and has
the right to grant licenses;

        WHEREAS, LICENSEE wishes to collaborate with the UNIVERSITY and to perform
further internal research and development on the SAMPLES & TECHNICAL
INFORMATION, as part of its effort to develop commercial products in the FIELD
that will be related to, rely on, using, incorporating and/or referencing the
SAMPLES & TECHNICAL INFORMATION;

        WHEREAS, LICENSEE wishes to obtain and PSRF is willing to grant a license
to said SAMPLES & TECHNICAL INFORMATION under the terms and conditions as set
forth herein;

        NOW THEREFORE, in consideration of the mutual promises and covenants set
forth herein and for good and valuable consideration, the adequacy and
sufficiency of which is hereby acknowledged, the parties hereby agree as
follows:

                                       1

                             ARTICLE I - DEFINITIONS

        For purposes of this License Agreement, the following words and phrases
shall have the following meanings:

        1.1 "LICENSEE" shall be DNAPrint Genomics Inc..

        1.2 "FIELD" shall mean the research, development and commercialization of
genomic informational kits for purposes of identifying eye colors, hair colors,
skin pigmentation, skin response to burn, for uses in forensics and prenatal
diagnostic.

        1.3 "TERRITORY" shall mean the countries in which PATENT RIGHTS shall apply.

        1.4 "PATENT RIGHTS" shall mean any and all pending and issued U. S. and
foreign counterparts of patent application filed and prosecuted pursuant to
Article 6; and all pending and issued renewals, continuations, divisions, and/or
reissues of such application or foreign counterparts filed and prosecuted
pursuant to Article 6, as a result of LICENSEE's collaboration with the
UNIVERSITY and the LICENSEE's internal research, development and
commercialization of LICENSED PRODUCT(s) relating to, relying on, using,
incorporating and/or referencing SAMPLES & TECHNICAL INFORMATION.

        1.5 "SAMPLES & TECHNICAL INFORMATION" shall mean certain human DNA samples
and certain subjectively measured and self-reported biogeographical ancestry and
ethnicity data, eye color, hair color & skin color pigmentation data, and sun
exposure history information relating to said samples, and is described in
Appendix B attached herein below.

        1.6 "LICENSED PRODUCT" shall mean any process, product or part thereof, or
use of a product or part thereof, which is researched and developed from,
relating to, relying on, using, incorporating and referencing SAMPLES &
TECHNICAL INFORMATION, and/or which is covered in whole or in part by at least
one unexpired claim of PATENT RIGHTS in the country in which any such process,
product or part thereof is made, used, or sold.

        1.7 "NET SALES" for LICENSED PRODUCT shall mean: (1) the revenue derived
from the sale, lease, transfer or consignment of LICENSED PRODUCT by LICENSEE to
independent third parties less the following amounts: (i) all normal and
customary discounts in the trade (i.e. cash discounts, volume discounts and
rebates); and (ii) credits or allowances actually granted upon claims or
returns; each determined in accordance with generally accepted accounting
principles consistently applied.

                            ARTICLE II - THE LICENSE

        2.1 Subject to any preexisting rights, if any, of the Government of the
United States created by the use of Government funding, PSRF hereby grants to
LICENSEE an exclusive right and license in the TERRITORY for the FIELD, without
right to sublicense, to SAMPLES & TECHNICAL INFORMATION and PATENTS RIGHTS and

                                       2

to the extent not prohibited by other patents, to collaborate with the
UNIVERSITY and to research, develop, make, have made, use, lease, and sell
LICENSED PRODUCTs for the term set forth herein, unless this License Agreement
shall be earlier terminated according to the terms and conditions contained
herein. Said SAMPLES & TECHNICAL INFORMATION shall be made available to LICENSEE
within XXXXX days from the Effective Date of this Agreement.

        2.2 PSRF reserves the rights for itself and the UNIVERSITY to use SAMPLES &
TECHNICAL INFORMATION and to practice under the PATENT RIGHTS for their own
research and educational purposes, including, without limitation, any new
information, methods and compositions developed, whether patentable or not, as a
result of the use of SAMPLES & TECHNICAL INFORMATION by the collaborative
efforts and LICENSEE's internal research efforts contemplated under this
Agreement.

        2.3 LICENSEE agrees that LICENSED PRODUCTs leased or sold in the United
States will be manufactured substantially in the United States. Certain PATENT
RIGHTS resulted from federally-supported research, and their assignment is
governed by the applicable provisions of the Federal funding agreements,
including the 35 USC Chapter 18 (the "Bayh-Dole Act"), 37 CFR Part 401.

        2.4 The license rights granted hereunder shall not be construed to confer
any rights upon LICENSEE by implication, estoppel or otherwise to any technology
owned or controlled by PSRF which is not specifically set forth herein.

        2.5 Except as set forth in Paragraph 2.2 above, the LICENSEE by acceptance
of granted said license rights hereunder shall not be construed to confer any
rights to PSRF, the UNIVERSITY or any of either's agents, employees or other
collaborators by implication, estoppel or otherwise to any technology owned,
controlled, licensed or otherwise obtained by LICENSEE and it's affiliates,
successors, sub-licensees, joint venture partners or other business partners yet
to be defined or controlled in part or in whole by LICENSEE which is not
specifically set forth herein.

                             ARTICLE III - PAYMENTS

        3.1 In partial consideration of the rights granted by this License
Agreement, LICENSEE shall pay to PSRF a non-refundable, License Issue Fee of ten
thousand one hundred and fifty dollars ($10,150.00 USD) upon execution of this
License Agreement. Said License Issue Fee shall be paid upon the Effective Date
of this License Agreement.

        3.2 In addition to the foregoing License Issue Fee, LICENSEE shall pay PSRF
a running royalty of twenty-five percent (25%) of NET SALES of LICENSED PRODUCTS
within the field of skin pigmentation. Such running royalties shall be payable
as provided in Paragraph 3.6.

                                       3

        3.3 In the event that the running royalties paid on NET SALES in any
calendar year do not reach the minimum amount set out below for such year,
LICENSEE shall pay an additional amount with the payment due for the period
ending December 31 of such year, so that the total amount paid for such year
shall reach such minimum amount:

                  Year One (2003)                    $2,500
                  Year Two (2004)                    $5,000
                  Year Three (2005)                  $10,000
                  Year Four (2006)                   $20,000
                  Year Five and after (2007-)        $40,000

        3.4 In addition to the foregoing License Issue Fee, Running Royalties and
Annual Minimum Royalties as set forth above in Paragraphs 3.1, 3.2 and 3.3,
LICENSEE shall pay PSRF Additional Running Royalties of three and a half percent
(3.5%) of NET SALES as defined herein for LICENSED PRODUCTS sold within the
field of eye and hair pigmentation

        3.5 Payment of the royalties specified in Paragraphs 3.2 and 3.4 shall be
made by LICENSEE to PSRF within thirty (30) days after June 30 and December 31
of each year during the term of this License Agreement covering the quantity of
LICENSED PRODUCTs sold by LICENSEE during the preceding calendar quarter. After
termination or expiration of this License Agreement, a final payment shall be
made by LICENSEE covering the whole or partial semi-annual period. Each
semi-annual payment shall be accompanied by a written statement of NET SALES as
described in Paragraph 5.2 hereunder.

        3.6 All payments due hereunder are expressed in and shall be paid by check
payable in United States of America currency, without deduction of exchange,
collection or other charges, to PSRF in University Park, PA or at such other
place as PSRF may reasonably designate.

        3.7 For converting into United States dollars any payment accrued hereunder
in the currency of any other country, the rate of exchange for the purchase of
United States dollars with such currency quoted by The Chase Manhattan Bank, New
York, New York, on the last business day of the payment period in question shall
be used.

        3.8 No multiple royalties shall be payable because any LICENSED PRODUCTs,
their manufacture, use, lease or sale are or shall be covered by more than one
patent application, patent or certificate of registration licensed under this
License Agreement.

        3.9 All payments set forth in this Agreement shall, if overdue, bear
interest until payment at a per annum rate of 2% above the prime rate in effect
at the Chase Manhattan Bank on the due date. The payment of such interest shall
not foreclose PSRF from exercising any other rights it may have as a consequence
of the lateness of any payment.

                                       4

        3.10 LICENSEE's failure to make payments in accordance with this Article
III shall constitute a material breach or default and shall be grounds for
termination of this License Agreement pursuant to Paragraph 14.3 hereof.

                         ARTICLE IV - MARKETING EFFORTS

        4.1 LICENSEE shall use reasonable efforts to diligently collaborate with
the UNIVERSITY, perform further research and development on SAMPLES & TECHNICAL
INFORMATION, and bring one or more LICENSED PRODUCTS into the commercial market
as soon as practicable, and to continue active, diligent marketing efforts for
one or more LICENSED PRODUCTS throughout the term of this License Agreement.
Such efforts shall include, but not be limited to the following actions:

                (a) LICENSEE shall promptly genotype the speciments for genetic loci
as part of LICENSEE's pigmentation battery;

                (b) within one (1) year from the Effective Date of this License
Agreement, LICENSEE shall have screened the SAMPLES & TECHNICAL INFORMATION
against at least 200 single nucleotide polymorphism (SNP) loci and
identified any statistical associations that may exist;

                (c) within two (2) years from the Effective Date of this License
Agreement, LICENSEE shall have shall have developed at least one (1)
prototype of LICENSED PRODUCT, given that significant statistical
associations are found under 4.1 (b) above;

                (d) within three (3) years from the Effective Date of this License
Agreement, LICENSEE shall have optimized the prototype LICENSED PRODUCT and
brought at least one (1) LICENSED PRODUCT to the commercial market;

                (e) publish and distribute a product circular for one or more LICENSED
PRODUCTs;

                (f) advertise in at least on major journal during the first year of
the introduction of one or more LICENSED PRODUCTs and twice annually for
five (5) years thereafter; and

                (g) market the LICENSED PRODUCTs with the same diligence as LICENSEE
employs for comparable products marketed by LICENSEE.

        4.2 LICENSEE's failure to perform in accordance with Paragraphs 4.1 shall
constitute a material breach or default and shall be grounds for termination of
this License Agreement pursuant to Paragraph 14.4 hereof.

                                       5

        4.3 In the event that LICENSEE in its sole discretion decides to market one
or more LICENSED PRODUCTs in any country, then LICENSEE shall exert reasonable
efforts to have such LICENSED PRODUCTs cleared for marketing by the responsible
government agencies of that country requiring such clearance. Should LICENSEE
terminate this License Agreement, LICENSEE agrees to assign its full right,
title, and interest in and to such market clearance application, including all
data relating thereto, to PSRF at no cost to PSRF.

                         ARTICLE V - REPORTS AND RECORDS

        5.1 LICENSEE shall keep and preserve, in accordance with generally accepted
accounting principles and procedures, complete and accurate books, records and
accounts containing all particulars that may be necessary for the purpose of
showing the amounts payable to PSRF hereunder. Said books, records and accounts
shall be kept at LICENSEE's principle place of business or the principle place
of business of the appropriate division of LICENSEE to which this License
Agreement relates. Said books and supporting data shall be open, upon reasonable
notice at all reasonable times and places during business hours for five (5)
years following the end of the calendar year to which they pertain, to the
inspection of PSRF or its agents for the purpose of verifying LICENSEE's royalty
statement or compliance in other respects with this License Agreement. Should
such inspection lead to the discovery of a greater than ten (10%) discrepancy in
reporting to PSRF's detriment, LICENSEE agrees to reimburse PSRF for the full
cost of such inspection.

        5.2 LICENSEE shall, within thirty (30) days of June 30 and December 31, of
each year, deliver to PSRF true and accurate reports, giving such particulars of
the business conducted by LICENSEE during the preceding calendar quarter under
this License Agreement as shall be pertinent to a royalty accounting hereunder.
These reports shall be duly signed by an authorized signatory of LICENSEE on
behalf of LICENSEE and shall include at least the following:

        (a) number and type of LICENSED PRODUCTs manufactured and sold by LICENSEE;

        (b) total billings for LICENSED PRODUCTs sold by LICENSEE;

        (c) listing of applicable deduction as provided in paragraph 1.6 hereinabove; and

        (d) total royalties due.

        5.3 With each such report submitted, LICENSEE shall pay to PSRF the
royalties due and payable under this License Agreement. If no royalties shall be
due, LICENSEE shall so report.

        5.4 LICENSEE shall use the royalty reporting sheet attached hereto as
Appendix A, or a substantial equivalent, to fulfill the royalty and reporting
requirements of this Article V.

                                       6

                      ARTICLE VI - PATENT RIGHTS OWNERSHIP,
                           PROSECUTION AND MAINTENANCE

        6.1 Ownership of PATENT RIGHTS. PSRF and LICENSEE shall be joint owners and
joint named assignees of all PATENT RIGHTS filed, prosecuted and maintained as a
result of LICENSEE's collaboration with the UNIVERSITY and LICENSEE's research
and development work relating to, relying on, using, incorporating and
referencing SAMPLES & TECHNICAL INFORMATION.

        6.2 Responsibility for Patent Prosecution. LICENSEE shall apply for, seek
prompt issuance of, and maintain the PATENT RIGHTS during the term of this
Agreement. The prosecution, filing and maintenance of patent applications and
patents which issue therefrom shall be the primary responsibility of LICENSEE,
or its designee, but PSRF shall be given the opportunity and reasonable time,
but not to exceed thirty (30) days from receipt of said patent applications, to
review and comment upon the breadth and coverage of said patent applications.
During the patent preparation, prosecution and maintenance process, PSRF shall
have reasonable opportunities to advise LICENSEE to ensure that said PATENT
RIGHTS adequately address the needs and desires of PSRF. LICENSEE shall provide
to PSRF copies of all correspondences to and from the law firm designated by
LICENSEE and all communications to and from patent offices relevant to the
filing, prosecution and maintenance of PATENT RIGHTS.

        6.3 U.S. Patent Filings. LICENSEE shall be responsible for all reasonable
and ordinary fees and external costs relating to the filing, prosecution,
maintenance and defense of U.S. provisional and non provisional applications and
resulting patents, pursuant to the conditions set forth herein. LICENSEE shall
promptly provide to PSRF copies of invoices for all such expenses.

        6.4 International Patent Filings. LICENSEE understands and agrees that the
primary responsibility for the filing, prosecution, maintenance and costs of all
foreign patent filings shall be LICENSEE's. LICENSEE shall consult PSRF no later
than three (3) months before applicable bar dates, as to the foreign countries
in which it wishes to continue to seek patent protection. Payment of all fees
and costs relating to the filing, prosecution, maintenance and defense of said
foreign patent rights shall be the direct responsibility of LICENSEE, provided
PSRF is kept reasonably informed and given advance estimates where practical.
LICENSEE shall promptly provide to PSRF copies of invoices for all such
expenses.

        6.5 Patent Expense Reimbursement. LICENSEE may retain up to fifty percent
(50%) of NET SALES as defined in Paragraph 1.7 to reimburse for patent expenses
as outlined in Paragraphs 6.3 and 6.4 above.

        6.6 Abandonment. In the event LICENSEE decides not to financially support,
or to continue prosecution of a patent application to issuance, or to maintain
any United States or foreign patent application within the PATENT RIGHTS,
LICENSEE shall timely notify PSRF in writing in order that PSRF may continue
said prosecution or maintenance of such intellectual property at its own
expense. LICENSEE's right under this License Agreement to any claims contained
within the PATENT RIGHTS for any country in which LICENSEE does not continue

                                       7

prosecution or maintenance in accordance with Paragraph 6.3 or 6.4 above shall
immediately terminate upon failure of LICENSEE to pay costs hereunder, but only
for the applicable country or countries.

        6.7 Grounds for Material Breach. LICENSEE's failure to make payments in
accordance with Paragraph 6.3 and 6.4, together with its failure to notify PSRF
of its intention to abandon PATENT RIGHTS under Paragraph 6.6, shall constitute
a material breach or default and shall be grounds for termination of this
License Agreement pursuant to Article XII hereof.

                  ARTICLE VII - INFRINGEMENT AND OTHER ACTIONS

        7.1 LICENSEE and PSRF shall promptly provide written notice, to the other
party, of any alleged infringement by a third party of any patent licensed
hereunder under PATENT RIGHTS and provide such other party with any available
evidence of such infringement.

        7.2 During the term of the License Agreement, LICENSEE shall have the
initial right, but not the obligation, to prosecute and/or defend, at its own
expense and utilizing counsel of its choice, any infringement of, and/or
challenge to, the PATENT RIGHTS. In furtherance of such right, LICENSEE hereby
agrees that PSRF may join LICENSEE as a party in any such suit, without expense
to PSRF. Such right to bring such an infringement action shall remain in effect
only for so long as the license granted herein remains exclusive. No settlement,
consent judgment or other voluntary, final disposition of the suit may be
entered into without the consent of PSRF, which consent shall be timely given
and not unreasonably be withheld. LICENSEE agrees to keep PSRF reasonably
informed as to the status of any such action and to provide copies to PSRF, upon
request by PSRF, of any papers or information relevant to the prosecution of any
such action. LICENSEE shall timely inform PSRF of any offer for settlement
presented by a third party for any such action and LICENSEE shall consider
PSRF's input in deciding whether or not to accept any such settlement offer. The
total cost of any such action, commenced or defended solely by LICENSEE, shall
be borne by LICENSEE, which shall keep any recovery or damages derived
therefrom.

        7.3 If within six (6) months after having been notified of any alleged
infringement, LICENSEE shall have been unsuccessful in persuading the alleged
infringer to desist and shall not have brought and shall not be diligently
prosecuting an infringement action, or if LICENSEE shall notify PSRF at any time
prior thereto of its intention not to bring suit against any alleged infringer
in the TERRITORY for the FIELD, then, and in those events only, PSRF shall have
the right, but not the obligation, at its own expense and utilizing counsel of
its choice, to prosecute any infringement of, and/or defend any challenge to,
the PATENT RIGHTS, and LICENSEE may, for such purposes, join PSRF as a party
plaintiff; provided, however, that such right to bring such an infringement
action shall remain in effect only for so long as the license granted herein
remains exclusive. No settlement, consent judgment or other voluntary, final
disposition of the suit may be entered into without the consent of LICENSEE,
which consent shall be timely given and not unreasonably be withheld. PSRF
agrees to keep LICENSEE reasonable informed as to the status of any such action
and to provide copies to LICENSEE, upon request by LICENSEE, of any papers or
information relevant to the prosecution of any such action. PSRF shall timely

                                       8

inform LICENSEE of any offer for settlement presented by a third party for any
such action and PSRF shall consider LICENSEE's input in deciding whether or not
to accept any such settlement offer. The total cost of any such action commenced
or defended solely by PSRF shall be borne by PSRF, which shall keep any recovery
or damages derived therefrom.

        7.4 In the event that a declaratory judgment action alleging invalidity or
noninfringement of any of the PATENT RIGHTS shall be brought against LICENSEE,
PSRF, at its option, shall have the right, within (30) days after commencement
of such action, to intervene and take over the sole defense of the action at its
own expense.

        7.5 In any infringement suit as either party may institute to enforce the
PATENT RIGHTS pursuant to this License Agreement, the other party hereto shall,
at the request and expense of the party initiating such suit, cooperate in all
respects and, to the extent possible, have its employees testify when requested
and make available relevant records, papers, information, samples, specimens,
and the like.

        7.6 With the written express consent of PSRF, LICENSEE, during the
exclusive period of this License Agreement, shall have the right in accordance
with the terms and conditions herein to sublicense any alleged infringer in the
TERRITORY for the FIELD for future use of the PATENT RIGHTS. Any upfront fees as
part of such a sublicense shall be shared equally between LICENSEE and PSRF;
other royalties shall be treated per Article III.

                         ARTICLE VIII - INDEMNIFICATION

        8.1 LICENSEE shall at all times during the term of this License Agreement
and thereafter, indemnify, defend and hold PSRF, its trustees, directors,
officers, employees and affiliates, harmless against all claims, proceedings,
demands and liabilities of any kind whatsoever, including legal expenses and
reasonable attorneys' fees, arising out of the death of or injury to any person
or persons or out of any damage to property, or resulting from the use or
reliance on SAMPLES & TECHNICAL INFORMATION, or the production, manufacture,
sale, use, lease, consumption or advertisement of the LICENSED PRODUCTs or
arising from any obligation of LICENSEE hereunder.

        8.2 Prior to the first commercial sale of a LICENSED PRODUCT, LICENSEE
shall obtain and carry in full force and effect commercial, general liability
insurance which shall protect LICENSEE and PSRF with respect to events covered
by Paragraph 8.1 above. Such insurance shall be written by a reputable insurance
company authorized to do business in the Commonwealth of Pennsylvania, shall
list PSRF as an additional named insured thereunder, shall be endorsed to
include product liability coverage and shall require thirty (30) days written
notice to be given to PSRF prior to any cancellation or material change thereof.
The limits of such insurance shall not be less than One Million Dollars
($1,000,000) per occurrence with an aggregate of Three Million Dollars
($3,000,000) for personal injury or death, and One Million Dollars ($1,000,000)
per occurrence with an aggregate of Three Million Dollars ($3,000,000) for
property damage. LICENSEE shall provide PSRF with Certificates of Insurance
evidencing the same.

                                       9

        8.3 EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS LICENSE AGREEMENT,
PSRF, ITS TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES, AND AFFILIATES MAKE NO
REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED,
INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE, VALIDITY OF PATENT RIGHTS CLAIMS, ISSUED OR PENDING, AND THE
ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE. NOTHING IN THIS
LICENSE AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION MADE OR WARRANTY GIVEN
BY PSRF THAT THE PRACTICE BY LICENSEE OF THE LICENSE GRANTED HEREUNDER SHALL NOT
INFRINGE THE PATENT RIGHTS OF ANY THIRD PARTY. IN NO EVENT SHALL PSRF, ITS
TRUSTEES, DIRECTORS, OFFICERS, EMPLOYEES AND AFFILIATES BE LIABLE FOR INCIDENTAL
OR CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING ECONOMIC DAMAGE OR INJURY TO
PROPERTY AND LOST PROFITS, REGARDLESS OF WHETHER PSRF SHALL BE ADVISED, SHALL
HAVE OTHER REASON TO KNOW, OR IN FACT SHALL KNOW OF THE POSSIBILITY.

                          ARTICLE IX - EXPORT CONTROLS

        9.1 It is understood that PSRF is subject to United States laws and
regulations controlling the export of technical data, computer software,
laboratory prototypes and other commodities (including the Arms Export Control
Act, as amended and the Export Administration Act of 1979), and that its
obligations hereunder are contingent on compliance with applicable United States
export laws and regulations. The transfer of certain technical data and
commodities may require a license from the cognizant agency of the United States
Government and/or written assurances by LICENSEE that LICENSEE shall not export
data or commodities to certain foreign countries without prior approval of such
agency. PSRF neither represents that a license shall not be required nor that,
if required, it shall be issued.

                          ARTICLE X - NON-USE OF NAMES

        10.1 LICENSEE shall not use the names or trademarks of Penn State, PSRF, or
any of their employees, or any adaptation thereof, in any advertising,
promotional or sales literature without prior written consent obtained from
PSRF, in each case, except that LICENSEE may, without prior written consent,
state that it is licensed by PSRF, under one or more of the patents and/or
applications comprising the PATENT RIGHTS.

             ARTICLE XI- PAYMENTS, NOTICES AND OTHER COMMUNICATIONS

        11.1 Any payment, notice or other communication pursuant to this License
Agreement shall be sufficiently made or given on the date of mailing if sent to
such party by certified or registered first class mail, postage prepaid,
addressed to it at its address below or as it shall designate by written notice
given to the other party as follows:

In the case of THE PENN STATE RESEARCH FOUNDATION:

                                       10

                           President
                           The Penn State Research Foundation
                           c/o Intellectual Property Office
                           113 Technology Center
                           University Park, PA  16802-7000
                           Phone:   814-865-6277
                           Fax:     814-865-3591

In the case of LICENSEE:

                           DNAPrint Genomics Inc.
                           900 Cocoanut Avenue
                           Sarasota, Florida 34236
                           Phone:   941-366-3400
                           Fax:     941-952-9770

                            ARTICLE XII - ASSIGNMENT

        12.1 This License Agreement shall not be assignable by either party without
the prior written consent of the other party except to a successor in ownership
of all or substantially all of the business assets of a party hereto, and which
successor shall expressly assume in writing the performance of all the terms and
conditions of this License Agreement to be performed by the assigning party.

                        ARTICLE XIII - DISPUTE RESOLUTION

        13.1 Except for the right of either party to apply to a court of competent
jurisdiction for a temporary restraining order, a preliminary injunction, or
other equitable relief to preserve the status quo or prevent irreparable harm,
any and all claims, disputes or controversies arising under, out of, or in
connection with this License Agreement, including any dispute relating to patent
validity or infringement, which the parties shall be unable to resolve within
sixty (60) days, shall be mediated in good faith. The party raising such dispute
shall promptly advise the other party of such claim, dispute or controversy in a
writing which describes in reasonable detail the nature of such dispute. By not
later than five (5) business days after the recipient has received such notice
of dispute, each party shall have selected for itself a representative who shall
have the authority to bind such party, and shall additionally have advised the
other party in writing of the name and title of such representative. By not
later than ten (10) business days after the date of such notice of dispute, the
party against whom the dispute shall be raised shall select a mediation firm in
Pennsylvania and such representatives shall schedule a date with such firm for a
mediation hearing. The parties shall enter into good faith mediation and shall
share the costs equally. If the representatives of the parties have not been
able to resolve the dispute within fifteen (15) business days after such
mediation hearing, the parties shall have the right to pursue any other remedies
legally available to resolve such dispute in either either the Centre County
Court of Common Pleas or in the United States District Court for the Middle
District of Pennsylvania, to whose jurisdiction for such purposes PSRF and
LICENSEE each hereby irrevocably consents and submits.

                                       11

        13.2 Notwithstanding the foregoing, nothing in this Article XIII shall be
construed to waive any rights or timely performance of any obligations existing
under this License Agreement.

                       ARTICLE XIV - TERM AND TERMINATION

        14.1 LICENSEE shall have the right to terminate this Agreement at any time
on six (6) months' notice to PSRF, and upon payment of all amounts due PSRF
through the effective date of the termination.

        14.2 Financial Solvency of LICENSEE. LICENSEE agrees that as a part of its
material inducement to PSRF to enter this License Agreement, it shall provide
PSRF with at least ninety (90) days written notice hereunder of its intent to
file a petition in Bankruptcy, whether it be for a Chapter 7, 11, 13 or any
other such petition. LICENSEE agrees and understands that PSRF has an obligation
to University, a land grant institution under the Morrell Act, to license the
PATENT RIGHTS pursuant to terms and conditions which maximize the public
benefit. PSRF shall have the right to immediately terminate this License
Agreement by giving written notice to LICENSEE, in the event LICENSEE does any
of the following: a) provides notice hereunder of its intent to file (or does
actually file without providing said notice) a petition in bankruptcy, b)
attempts to make an assignment hereof for the benefit of creditors, c)
discontinues or dissolves its business, or d) if a receiver is appointed for
LICENSEE.

        14.3 Financial Breach. In the event LICENSEE has breached its obligations
to pay royalties or fees under Article III of this License Agreement, and/or
fails to file royalty reports in accordance with Article V of this License
Agreement, (hereafter "Financial Breach") PSRF shall provide LICENSEE with
written notice of said breach, and LICENSEE shall have a period of thirty (30)
days to cure said breach. In the event LICENSEE does not fully cure the breach
within that thirty (30) day period, and fails within that thirty (30) days to
commence mediation pursuant to Article XIII of this License Agreement alleging
grounds for its non-payment thereof, this License Agreement shall be
automatically terminated without further notice or action by PSRF.
Notwithstanding LICENSEE's rights to cure herein, in the event LICENSEE commits
a Financial Breach more than two times within any calendar year within the term
of this License, PSRF shall be entitled to give notice of breach which shall
become effective immediately upon LICENSEE's receipt of said Notice, and for
which LICENSEE shall not have any further right of "cure."

        14.4 Failure of Other Performance. Upon any material breach of performance
under this License Agreement, by LICENSEE, other than those occurrences set out
in Paragraphs 14.2 or 14.3 hereinabove, which shall always take precedence in
that order over any material breach or default referred to in this Paragraph
14.4, PSRF shall have the right to terminate this License Agreement and the
rights, privileges and license granted hereunder effective sixty (60) days after
PSRF first notifies LICENSEE of the alleged breach under the notice provisions
contained in Article XIV of this License Agreement. As used in this License
Agreement, the term "Material Breach of Performance" shall include, but not be
limited to the following: breach of due diligence provisions in Article IV,
repeated inaccuracies of royalty reports, failure to notify PSRF of

                                       12

infringement, failure to assume duty to indemnify and defend, failure to provide
adequate levels of insurance, and attempt to assign rights hereunder. Such
termination shall become effective upon final notification by PSRF after the
sixty (60) days, unless LICENSEE shall have fully cured any such material breach
or default prior to the expiration of the sixty (60) day period. In the event of
a dispute as to whether LICENSEE has cured the alleged breach, the matter shall
be resolved pursuant to Article XIII of this License Agreement.

        14.5 Upon termination of this License Agreement for any reason, nothing
herein shall be construed to release either party from any obligation that
matured prior to the effective date of such termination; and Articles I, VIII,
IX, X, XV and paragraphs 14.5 and 14.6 shall survive any such termination.
LICENSEE may, however, after the effective date of such termination, sell all
LICENSED PRODUCTs, and complete LICENSED PRODUCTs in the process of manufacture
at the time of such termination and sell the same, provided that LICENSEE submit
the reports required by Article V hereof.

                      ARTICLE XV - MISCELLANEOUS PROVISIONS

        15.1 Entire Agreement. This License Agreement embodies the entire
understanding of the parties and shall supersede all previous communications,
representations, or undertakings, either verbal or written, between the parties
relating to the subject matter hereof.

        15.2 Amendment. This License Agreement may be amended only by a written
agreement embodying the full terms of the amendment signed by authorized
representatives of both parties.

        15.3 Severability. Should any provision of this License Agreement be held
to be illegal, invalid or unenforceable, by any court of competent jurisdiction,
such provision shall be modified by such court in compliance with the law and,
as modified, enforced. The remaining provisions of this License Agreement shall
be construed in accordance with the modified provision and as if such illegal,
invalid or unenforceable provision had not been contained herein.

        15.4 No Strict Construction. The language used in this License Agreement
shall be deemed to be the language chosen by both parties hereto to express
their mutual intent and no rule of strict construction against either party
shall apply to any term or condition of this License Agreement.

        15.5 Relationship of Parties. Nothing contained in this License Agreement
shall be construed as creating a partnership, joint venture, agency or an
association of any kind.

        15.6 No Waiver. The failure of one party hereto to enforce at any time any
of the provisions of this License Agreement, or any rights in respect thereto,
or to exercise any election herein provided, shall in no way be considered to be
a waiver of such provision, rights or elections or in any way to affect the
validity of this License Agreement, or excuse a similar subsequent failure to

                                       13

perform any such term or condition by the other party. Any waiver must be in
writing.

        15.7 Interpretation. The headings of several sections contained herein are
inserted for convenience of reference only, and are not intended to be a part of
or to affect the meaning or interpretation of this License Agreement.

        15.8 Governing Law. This License Agreement shall be governed by and
construed in accordance with the laws of the Commonwealth of Pennsylvania
without giving effect to any choice of law or conflict of law provision or rule
that would cause the application of the laws of any jurisdiction other than the
Commonwealth of Pennsylvania, except that questions affecting the construction
and effect of any patent shall be determined by the law of the country in which
the patent was granted.

        15.9 Product Marking. LICENSEE agrees to mark the LICENSED PRODUCTs sold in
the United States with all applicable United States patent numbers. All LICENSED
PRODUCTs shipped to or sold in other countries shall be marked in such a manner
as to conform with the patent laws and practices of the country of manufacture
or sale.

                                       14

IN WITNESS WHEREOF, the parties hereto, intending to be legally bound hereby,
have each caused a duly authorized representative to execute this License
Agreement on the day and year set forth below.

DNAPRINT GENOMICS INC.
(LICENSEE)

By:                    _____________________________________
Name:                     __________________________________
Title:                  ____________________________________
Date:                    ___________________________________

THE PENN STATE RESEARCH FOUNDATION
(PSRF)

By:                    _____________________________________
Name:                     __________________________________
Title:                  ____________________________________
Date:                    ___________________________________

Read and understood:

By:                    _____________________________________
Name:                    ______Dr. Mark Shriver_____________
Title:                  ____________________________________
Date:                    ___________________________________

                                       15

                                   Appendix A
[COMPANY]/PSRF License Agreement Royalty Report for the Period ____________through__________

Instructions: Please fill in all boxes (write "none" if not applicable), and
sign and date at bottom. All section numbers refer to the License Agreement.

Answer questions 1 and 2 (AND SIGN AND DATE AT BOTTOM) EVEN IF THERE HAS BEEN NO
ACTIVITY in reporting period.

1.  Number of transactions:         by [COMPANY]

Answer this section only if there has been Licensed Product/Process activity in
reporting period.

                                                      Product or Process                Deductions
    Date of      Type of Transaction    By ______     Type (name and id     Total         per  __      Royalties   Customer Name and Address
  Transaction                                              number)         Billings    (specify type)    Due

_____________________________________________________________________________________________________________________________________________

_____________________________________________________________________________________________________________________________________________

_____________________________________________________________________________________________________________________________________________

_____________________________________________________________________________________________________________________________________________

Number of Royalty Report continuation sheets attached________

Total amount enclosed  $_______________

[COMPANY]

By:________________________________________________           Date:_______________________________________

Name and Title:______________________________________________________________________________________

                                       16

                                   Appendix A

Continuation sheet number _____to [COMPANY]/PSRF License Agreement Royalty
Report for the Period _____________ through ________________ 

Use this sheet if there are additional transactions to report.

                                                      Product or Process                Deductions
    Date of      Type of Transaction    By ______     Type (name and id     Total         per  __      Royalties   Customer Name and Address
  Transaction                                              number)         Billings    (specify type)    Due

_____________________________________________________________________________________________________________________________________________

_____________________________________________________________________________________________________________________________________________

_____________________________________________________________________________________________________________________________________________

_____________________________________________________________________________________________________________________________________________

_____________________________________________________________________________________________________________________________________________

_____________________________________________________________________________________________________________________________________________

_____________________________________________________________________________________________________________________________________________

_____________________________________________________________________________________________________________________________________________

                                       17

                                   Appendix B

Samples to be transferred to DNAPrint Genomics from the Laboratory for
Anthropological Genomics, at PSU for the purposes of Pigmentary Trait Gene
Identification

                  Population Samples for the Proposed Research
Geographic Location                 Biogeographical                Current # of
      PI(s)                        Ancestry/Ethnicity                Subjects

Centre County, PA                73% European-American, 27%             397
                                 assorted
Guerro, and Sonora Mexico        Three isolated groups; low             203
                                 levels of admixture

TOTAL                                                                   600

We have also collected pigmentation data and DNA on a total of 203 subjects from
Mexico. These subjects have been measured using the DermaSpectrometer at the
inner arm, forehead, and hair. Questionnaire information includes self reported
eye color, hair color and sun exposure history. Additionally, photographs of
each subject are available for the objective estimation of eye color. DNA has
been extracted from each subject and is available for transfer to DNAPrint. Each
individual in this study gave informed consent prior to beginning the procedure,
and this research was performed under the approval of the Pennsylvania State
University IRB (IRB #00M0525-A0) and Penn State General Clinical Research Center
General Advisory Committee.

We have also evaluated 397 individuals living in State College, Pennsylvania for
constitutive skin color and a subset of these (n = 250) have been evaluated for
solar response. All of the volunteers were adults (i.e. at least 18 years of
age), with the average age of 24.5 years and a range of ages between 18 and 78
years. The sample included 244 females and 153 males. The majority of this
sample can be divided into three groups, European-American (n = 289), Hispanic
(n = 45), and East Asian (n = 29), based on self reported ancestry. A subset of
individuals from the larger sample were measured for responses to UVR;
European-American (n = 190), Hispanic (n = 45), and East Asian (n = 15). The
Hispanic group includes persons whose ancestry can be traced to Puerto Rico,
Colombia, Mexico, Honduras, Panama, and Guatemala. Each individual in this study
gave informed consent prior to beginning the procedure, and this research was
performed under the approval of the Pennsylvania State University IRB (IRB
#00M0558-A4) and Penn State General Clinical Research Center General Advisory
Committee.

The subjects in the State College sample have been assayed for a number of
phenotypes including skin and hair pigmentation with both the DermaSpectrometer
and the Microflash. Questionnaire information includes self reported eye color,
hair color and sun exposure history. Digital facial photographs were taken and
hair samples collected on most subjects. As noted above 250 of these subject
participated in the skin response phase of the study.

                                       18

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00042-of-00352.parquet"}]]